Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)

Adrie Bekker; Eric H Decloedt; Gretchen Slade; Mark F Cotton; Helena Rabie; Tim R Cressey

doi:10.1093/cid/ciaa1026

Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)

Clin Infect Dis. 2021 Jun 1;72(11):2032-2034. doi: 10.1093/cid/ciaa1026.

Authors

Adrie Bekker¹, Eric H Decloedt², Gretchen Slade¹, Mark F Cotton¹, Helena Rabie¹, Tim R Cressey^{3

4

5}

Affiliations

¹ Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
² Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
³ PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
⁴ Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
⁵ Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.

PMID: 32697327
DOI: 10.1093/cid/ciaa1026

Abstract

Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.

Keywords: HIV; abacavir; neonates; pharmacokinetics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-HIV Agents* / therapeutic use
Child
Dideoxynucleosides / therapeutic use
HIV
HIV Infections* / drug therapy
Humans
Infant
Infant, Newborn

Substances

Anti-HIV Agents
Dideoxynucleosides
abacavir